Figure 4.
Figure 4. Survival data depending on biogroup and TET2 status. (A) OS of biCEBPACCSneg, biCEBPACCSpos, and moCEBPA patients. (B) OS of biCEBPA patients depending on TET2 mutational status.

Survival data depending on biogroup and TET2 status. (A) OS of biCEBPACCSneg, biCEBPACCSpos, and moCEBPA patients. (B) OS of biCEBPA patients depending on TET2 mutational status.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal